Healio3d
Vanzacaftor, tezacaftor, deutivacaftor similar to current cystic fibrosis standard of care
Please provide your email address to receive an email when new articles are posted on . Percent-predicted FEV 1, sweat chloride and safety were analyzed in two phase 3 trials of vanzacaftor ...
FiercePharma27d
Vertex snags FDA nod for once-daily cystic fibrosis triplet Alyftrek as switch from Trikafta kicks off
As Vertex Pharmaceuticals reels from a painful trial readout for its pain candidate suzetrigine, the Boston biotech has chalked up a win in its specialty area of cystic fibrosis. The FDA has ...
Monthly Prescribing Reference23d
FDA Approval Increases Eligibility for Cystic Fibrosis Medication Trikafta
Participants were randomly assigned to receive Trikafta or placebo based on age and weight: Aged 6 to <12 years and less than 30kg: morning dose of elexacaftor 100mg/tezacaftor 50mg/ivacaftor 75mg ...
The Business Journals26d
Vertex wins approval for new once-daily CF drug
It will be marketed as Alyftrek. Vertex also won expanded approval for Trikafta, which was first approved in 2019. Trikafta has become Vertex’s (Nasdaq: VRTX) blockbuster CF drug, helping drive ...
Nasdaq29d
Vertex announces FDA exands approval for Trikafta
Vertex Pharmaceuticals (VRTX) announced the U.S. Food and Drug Administration has approved the expanded use of Trikafta for the treatment of people with cystic fibrosis ages 2 and older who have ...
Benzinga.com5d
Vertex Pharmaceuticals Sets Sight on Expanding Portfolio with Alyftrek Approval, Pain Treatment Progress, and Diabetes Trials
FDA approval of ALYFTREK and TRIKAFTA expands CF treatment options to over 300 mutations, benefiting 300 newly eligible U.S. patients. Suzetrigine for acute pain aligns with NOPAIN Act ...
Hosted on MSN14d
Saskatchewan expands Trikafta coverage for cystic fibrosis
Cystic fibrosis has traditionally been considered a fatal disease. But thanks to medical advancements and treatments, many patients now live longer, healthier lives. Patients in Saskatchewan may ...
Awful Announcing29d
Jeremy Schaap calls Boomer and Gunnar Esiason E:60 ‘one of the best things we’ve done’
30 years later, this remarkable story includes a breakthrough medicine, Trikafta, which is giving cystic fibrosis patients a second wind. “We keep coming back to the word miracle, but when you ...
ESPN26d
How hockey became a lifeline for Gunnar and Boomer Esiason
Courtesy of Gunnar Esiason After a few particularly nasty years battling CF, Gunnar entered into a clinical trial in 2018 for a drug called Trikafta, which had received funding from the Boomer ...
Everyday Health9d
Rheumatoid Arthritis Rashes: What You Need to Know
For many people with RA, its effects include rashes in different areas of the skin. In some cases, skin rashes are related to RA or RA treatments, but some skin issues aren’t connected to ...
AFP4d
Vertex Announces US FDA Approval of ALYFTREKâ„¢, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis
“In Phase 3 clinical trials, across a broad range of genotypes, once-daily ALYFTREK demonstrated non-inferiority to TRIKAFTA in ppFEV 1 response and statistically significant improvement in ...